SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a global leader in health technology focused on sleep, breathing, and home care, has announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience in leading investor engagement strategies at some of the world's leading health technology and financial services organizations. Her extensive background will be instrumental in advancing Resmed’s long-term strategic goals.
Experienced Leadership for Investor Relations
Salli Schwartz joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In this role, she was responsible for managing Illumina’s investor relations strategy, liaising with shareholders to address their perspectives on corporate strategy, capital allocation, and financial performance. Schwartz was also an integral member of Illumina’s Corporate Social Responsibility Executive Steering Committee and the Transformation Office, underscoring her ability to blend corporate governance with stakeholder engagement.
Schwartz’s expertise in investor relations extends beyond Illumina. Prior to her tenure there, she held the position of Head of Investor Relations and Treasurer at MSCI, Inc., where she led investor communications and managed a substantial portfolio worth over $6 billion in cash, short-term investments, and high-yield debt. Additionally, she was an active participant in MSCI’s Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee. Early in her career, Schwartz also contributed to strategic initiatives at Moody’s Corporation and Citigroup Inc., building a well-rounded understanding of both finance and corporate governance.
Strategic Vision to Drive Shareholder Value
“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Mick Farrell, Resmed’s Chairman of the Board and CEO. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”
As Resmed’s Chief Investor Relations Officer, Schwartz will oversee the company's global investor relations activities, serving as a key liaison between the company and its global investor community. She will report directly to Mick Farrell, guiding the company's engagement with shareholders and aligning its communication with long-term strategic goals.
Enhancing Resmed’s Commitment to Accessible Healthcare
Schwartz’s appointment comes at a pivotal time for Resmed, as the company advances its strategy to provide better sleep and breathing health solutions to individuals worldwide. Resmed is focused on pioneering innovative technology solutions that make home healthcare more personalized, accessible, and effective. With the recent expansion of its AI-powered digital health solutions and cloud-connected devices, Resmed is well-positioned to transform the healthcare experience for millions globally.
“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. The company is committed to pioneering innovative technology to empower millions of people across 140 countries to lead happier, healthier lives. Through its AI-powered digital health solutions, cloud-connected devices, and intelligent software, Resmed is shaping the future of home healthcare. The company envisions a world where every individual can achieve their full potential through improved sleep and breathing, with care delivered in their own home.